ClinicalTrials.gg
Active, not recruitingNCT06472076Updated Jul 21, 2026

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Dostarlimab and Belrestotug in Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline. Active, not recruiting at 108 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline — 1 open to participants now, 7 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · GlaxoSmithKline.

Enrollment
24th of 47
88 · median 88
Started
2024
the only one that year
Phase 3
7 of 54
1 open now
Registered
51st of 54
by date

Among the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, this one is the 24th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 3, and was the 51st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Carcinoma, Non-Small-Cell Lung by GlaxoSmithKline, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.

03

Conditions studied

  • Lung Cancer, Non-Small Cell

Keywords

  • Belrestotug
  • GSK4428859A
  • EOS-448
  • Dostarlimab
  • Pembrolizumab
  • PD-L1 selected NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of locally advanced, unresectable NSCLC (not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy), or NSCLC
  • Has not received prior systemic therapy for their locally advanced or metastatic NSCLC.
  • Provides a fresh tumor tissue sample obtained at the time of or after the initial diagnosis of locally advanced or metastatic NSCLC.
  • Has a -high (Tumor cells [TC] ≥50%) tumor
  • Has (at least 1 target lesion) based on 1.1
  • Has an (ECOG) Performance status (PS) score of 0 or 1.
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has NSCLC with a tumor that harbors any of the following molecular alterations:

    1. Epidermal growth factor receptor (EGFR) mutations that are sensitive to available targeted inhibitor therapy
    2. Anaplastic lymphoma kinase (ALK) translocations that are sensitive to available targeted inhibitor therapy
    3. Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for treatment of locally advanced or NSCLC.
  • Has had surgery within 4 weeks of the first dose of study intervention and has not recovered from AEs (i.e., has any ongoing surgery-related events ≥ Grade 1)/complications related to surgery or has received lung radiation therapy of >30 gray (Gy) within 6 months
  • Has received prior therapy with any , including antibodies or drugs targeting PD-(L)1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoglobulin and ITIM domain (TIGIT), or other checkpoint pathways.
  • Has never smoked, defined as smoking \<100 tobacco cigarettes in a lifetime.
  • Has an invasive or history of invasive malignancy other than the disease under study within the last 5 years, with the exception of those with a negligible risk of metastasis or death and/or treated with expected curative outcome.
  • Has symptomatic, untreated, or actively progressin g or
  • Has disease or syndrome (current or history thereof) that required systemic treatment within the past 2 years.
  • Has received any within 30 days prior to first dose of study intervention.
  • Has any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis.
  • Has symptomatic ascites, pleural effusion, or pericardial effusion.
  • Has active inflammatory bowel disease
  • Has a history of significant acute or chronic cardiac diagnosis requiring intervention/treatment in the last 6 months.
  • Has severe infection or complication thereof 4 weeks prior to randomisation including active tuberculosis.
  • Has a history of allogeneic tissue/stem cell transplant or solid organ transplant.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Dostarlimab plus belrestotug

    Biological: Dostarlimab · Biological: Belrestotug

  • Active comparator
    Pembrolizumab plus placebo

    Biological: Pembrolizumab · Drug: Placebo

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered.

  • BiologicalBelrestotug

    Belrestotug will be administered.

  • BiologicalPembrolizumab

    Pembrolizumab will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to approximately 138 weeks

  2. Number of Participants with TEAEs or SAEs leading to dose withdrawals or treatment discontinuation

    Time frame: Up to approximately 138 weeks

07

Study locations

108 sites
  • GSK Investigational Site
    Ocala, Florida 34474, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96819, United States
  • GSK Investigational Site
    Lexington, Kentucky 40503, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Omaha, Nebraska 68114, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Olympia, Washington 98506, United States
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Cipoletti Rio Negro, R8324CVE, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1426AGE, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABI, Argentina
  • GSK Investigational Site
    Córdoba, 5000, Argentina
  • GSK Investigational Site
    Florida, 1602, Argentina
  • GSK Investigational Site
    Mendoza, M5500AYB, Argentina
  • GSK Investigational Site
    Rosario, S2002, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, T4000, Argentina
  • GSK Investigational Site
    Hasselt, 3500, Belgium
  • GSK Investigational Site
    Mont Gaston, 5530, Belgium
  • GSK Investigational Site
    Barretos, 14784-400, Brazil
  • GSK Investigational Site
    Belém, 66.073-005, Brazil
  • GSK Investigational Site
    CuritibaPR, 80810-050, Brazil
  • GSK Investigational Site
    Florianópolis, 88034-000, Brazil
  • GSK Investigational Site
    Fortaleza, 60336-232, Brazil
  • GSK Investigational Site
    Londrina, 86015-520, Brazil
  • GSK Investigational Site
    Porto VelhoRondOnia, 76.834-899, Brazil
  • GSK Investigational Site
    Salvador, 40414-120, Brazil
  • GSK Investigational Site
    SAo JosE Do Rio PretoSP, 15090-000, Brazil
  • GSK Investigational Site
    São Paulo, 04312903, Brazil
  • GSK Investigational Site
    Vitória, 29043-260, Brazil
  • GSK Investigational Site
    Haskovo, 6300, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4004, Bulgaria
  • GSK Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • GSK Investigational Site
    Chengdu, 610000, China
  • GSK Investigational Site
    Hangzhou, 310006, China
  • GSK Investigational Site
    Hangzhou, China
  • GSK Investigational Site
    Hefei, 230001, China
  • GSK Investigational Site
    Nanjing, 210006, China
  • GSK Investigational Site
    Shanghai, 200030, China
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Angers, 49000, France
  • GSK Investigational Site
    Boulogne-Billancourt, 92100, France
  • GSK Investigational Site
    Limoges, 87042, France
  • GSK Investigational Site
    Lorient, 56100, France
  • GSK Investigational Site
    Pessac, 33064, France
  • GSK Investigational Site
    Rennes, 35033, France
  • GSK Investigational Site
    Hamburg, 20251, Germany
  • GSK Investigational Site
    Shatin, Hong Kong
  • GSK Investigational Site
    Gokul Shirgoan, Kolhapur 416234, India
  • GSK Investigational Site
    Apex Wellness Hospital, 422005, India
  • GSK Investigational Site
    Bangalore, 560085, India
  • GSK Investigational Site
    Belagavi, 590010, India
  • GSK Investigational Site
    Bhubaneswar, 751007, India
  • GSK Investigational Site
    Gurgaon, 122001, India
  • GSK Investigational Site
    New Delhi, 110075, India
  • GSK Investigational Site
    Aichi, 466-8560, Japan
  • GSK Investigational Site
    Ehime, 790-0024, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Hokkaido, 062-0931, Japan
  • GSK Investigational Site
    Hyōgo, 665-0827, Japan
  • GSK Investigational Site
    Kyoto, 612-8555, Japan
  • GSK Investigational Site
    Mie, 515-8544, Japan
  • GSK Investigational Site
    Miyagi, 981-0914, Japan
  • GSK Investigational Site
    Nagasaki, 852-8501, Japan
  • GSK Investigational Site
    Niigata, 951-8566, Japan
  • GSK Investigational Site
    Osaka, 596-8501, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Tokyo, 162-8655, Japan
  • GSK Investigational Site
    Tottori, 683-8504, Japan
  • GSK Investigational Site
    Wakayama, 641-8510, Japan
  • GSK Investigational Site
    Guadajalara, 44280, Mexico
  • GSK Investigational Site
    La Paz BCS, 23040, Mexico
  • GSK Investigational Site
    Mexico City, 06700, Mexico
  • GSK Investigational Site
    San Luis Potosí City, 78209, Mexico
  • GSK Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • GSK Investigational Site
    Enschede, 7512 KZ, Netherlands
  • GSK Investigational Site
    Panama City, Panama
  • GSK Investigational Site
    Punta Pacifica Panama City Panama, Panama
  • GSK Investigational Site
    Daegu, 41404, South Korea
  • GSK Investigational Site
    Incheon, 21565, South Korea
  • GSK Investigational Site
    Seoul, 02841, South Korea
  • GSK Investigational Site
    Seoul, 05505, South Korea
  • GSK Investigational Site
    Seoul, 08308, South Korea
  • GSK Investigational Site
    Seoul, 120-752, South Korea
  • GSK Investigational Site
    A Coruña, 15006, Spain
  • GSK Investigational Site
    Aravaca, 28013, Spain
  • GSK Investigational Site
    BaracaldoVizcaya, 48903, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08023, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Jaén, 23007, Spain
  • GSK Investigational Site
    Las Palmas de Gran Canar, 35016, Spain
  • GSK Investigational Site
    Madrid, 28010, Spain
  • GSK Investigational Site
    Madrid, 28033, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
  • GSK Investigational Site
    Oviedo, 33006, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain

Showing the first 100 of 108 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2026, 24 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 24 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jun 24, 2024
StartActual
Jun 10, 2024
Primary completionActual
Jun 30, 2026
CompletionEst.
Aug 30, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06472076
Lead sponsor
GlaxoSmithKline
Collaborators
iTeos Therapeutics
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jun 10, 2024
Primary completion
Jun 30, 2026
Completion
Aug 30, 2027 (estimated)
Last update
Jul 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Belrestotug

Start the discussion